← Evidence map

ArticleJournal of interventional cardiology2017

The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

Devraj Sukul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). | OpenQuestion